This does not mean that SIRT3 is not a suitable candidate for anti-cancer therapy development, but its application may be limited or restricted to those tumors that have reprogrammed their mitochondrial machinery towards a “Warburg phenotype” and may benefit from a rewire of their metabolism. This evidence concerns the gene SIRT3 and cancer.